Elevated serum PRDX6 levels have previously been reported in patients with MS and neuromyelitis optica spectrum disorder (NMOSD) compared to those with other neurological disorders, such as amyotrophic lateral sclerosis and spinocerebellar degeneration. Here, PRDX6 is linked to myeloid sarcoma.